RECURSION PHARMACEUTICALS, INC. 8-K

What Happened

• Recursion Pharmaceuticals (RXRX) filed an 8-K on March 25, 2026 and issued a press release announcing a leadership change in its clinical organization. Vicki Goodman, M.D., will become the company’s Chief Medical Officer effective April 6, 2026. Current CMO David Mauro, M.D., Ph.D., is transitioning out of the role and will remain with the company in an advisory capacity through May 29, 2026.

Key Details

• Filing date: March 25, 2026 (8-K and accompanying press release).
• New CMO start date: April 6, 2026 (Vicki Goodman, M.D.).
• Outgoing CMO advisory period: David Mauro will serve as advisor until May 29, 2026.
• The disclosure was made under executive change/Regulation FD items in the 8-K (press release included as an exhibit).

Why It Matters

• The CMO leads clinical development and interactions with regulators, so this change affects who directs Recursion’s clinical programs and trial execution.
• Investors should note the transition timeline (immediate CMO change with a six‑week advisory overlap) and watch for future filings or company updates that describe Dr. Goodman’s responsibilities, strategic priorities, or any impact on clinical milestones and development timelines.